Table 3.
Relationships between both the eGFR at age 88 years and the decrease in the eGFR 3 years before (between age 85 and 88) and total and cardiovascular (CV) mortality
|
eGFR slope per year between 85 and 88 years in ml/min/1.73 m2/year |
|||||
|---|---|---|---|---|---|
| >-1 | -1 to -2.99 | -3 to -4.99 | <-5 | ||
|
eGFR at age 88 > 60 (n=169) |
|
n=128 |
n=26 |
n=12 |
n=3 |
|
Overall mortality |
1 (ref) |
1.37 (0.82-2.31) |
2.17 (1.08-4.40) |
2.63 (0.79-8.76) |
|
|
CV mortality |
1 (ref) |
1.10 (0.39-3.05) |
2.99 (1.02-9.07) |
8.35 (2.15-32.46) |
|
|
eGFR at age 88 45–59 (n=147) |
|
n=71 |
n=46 |
n=21 |
n=9 |
|
Overall mortality |
1 (ref) |
0.77 (0.47-1.26) |
1.27 (0.69-2.35) |
3.16 (1.44-6.95) |
|
|
CV mortality |
1 (ref) |
0.89 (0.38-2.07) |
0.67 (0.18-2.78) |
4.23 (1.22-14.65) |
|
| eGFR at age 88 < 45 (n=62) | |
n=20 |
n=21 |
n=14 |
n=7 |
|
Overall mortality |
1 (ref) |
0.63 (0.31-1.26) |
0.54 (0.18-1.61) |
2.03 (0.59-7.02) |
|
| CV mortality | 1 (ref) | 0.99 (0.39-2.55) | 0.34 (0.04-2.76) | 4.72 (1.21-18.47) | |
The results are presented as the HR (95% CI) and were adjusted for gender and the mean of the eGFR at ages 85 and 88. The results are shown with one reference group for each eGFR subgroup.
* No events.